Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04492735
Other study ID # PSORC ICG
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 5, 2020
Est. completion date June 2025

Study information

Verified date July 2020
Source Children's Hospital Medical Center, Cincinnati
Contact Erin Watters
Phone 513-803-7024
Email erin.watters@cchmc.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to:

1. Diagnostic accuracy using pathologic correlation as gold standard measure

2. Short and long term event free and overall survival


Description:

Patients diagnosed with solid malignancies or metastatic lesions who require clinically indicated resection will be identified by their Oncologist. The oncologist will inform the subject/family about the study and ask if they may be interested in participating. If the subject/family demonstrates potential interest in the study, the Pediatric Surgery Research team will discuss the risks and benefits of pre-operative ICG administration with the patients and enrollment.

Study subjects: All patients diagnosed with solid malignancies as well as those with metastatic disease distant from the primary tumor will be potentially eligible for the study. Diagnosis will be made:

1. In a multimodal fashion including physical exam, radiologic evaluation (ultrasound, MRI, CT scan, etc), and sometimes biopsy.

2. Prior to definitive surgical resection of the newly diagnosed malignancy


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date June 2025
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 45 Years
Eligibility Inclusion Criteria:

All patients with newly diagnosed solid, primary malignancies or their related metastatic lesions.

Diagnosis of primary or metastatic malignancy will be made by combination of:

1. Clinical evaluation and physical exam

2. Radiologic study including ultrasound, CT scan, and/or MRI

3. Pathologic diagnosis after biopsy

Exclusion Criteria:

1. Those patients and parents/guardians unwilling to provide consent/assent.

2. Pregnant and/or women who are breast feeding.

3. Patients with Iodine allergies

Study Design


Locations

Country Name City State
United States Cincinnati Childrens Hospital Medical Center Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
Roshni Dasgupta

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy using pathologic correlation as gold standard measure 2 years
Primary Short and long term event free and overall survival 2 years
See also
  Status Clinical Trial Phase
Terminated NCT01450683 - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy Phase 2
Terminated NCT04116164 - Safety and Targeting of Anti-hk2 Antibody in mCRPC Early Phase 1
Completed NCT04595032 - MAnagement of METastatic Disease In Campania (MAMETIC)
Terminated NCT01020305 - Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer Phase 1/Phase 2
Withdrawn NCT02496832 - A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo N/A
Completed NCT01763970 - Stereotactic Radiation Therapy for Pediatric Sarcomas N/A
Completed NCT01703910 - Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic Phase 2
Completed NCT00609401 - Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) Phase 2
Completed NCT02628379 - Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
Completed NCT00480389 - Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal Phase 2
Recruiting NCT03632005 - Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery N/A
Terminated NCT02175654 - Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab Phase 2
Not yet recruiting NCT01861938 - Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Phase 2/Phase 3
Completed NCT01875380 - Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT00532454 - Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen Phase 2
Terminated NCT02795819 - Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Phase 1
Recruiting NCT05188911 - Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Completed NCT03823989 - Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients Phase 1
Terminated NCT01904916 - CPCT-05 Biopsy Protocol Patient Selection N/A
Terminated NCT01484860 - Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy Phase 2